Pfizer is testing three extra-small doses of its vaccine in
children under 5 after two shots didn’t prove quite strong enough. Initial
results had been expected last month but the company laid out the latest
timeline Tuesday during its discussion of quarterly financial results.
Currently in the U.S., only children ages 5 or older can be
vaccinated, using Pfizer’s vaccine -- leaving 18 million younger tots
unprotected.
Rival Moderna hopes to be the first to offer vaccinations
for the youngest children. Last week, it filed with the Food and Drug
Administration data it hopes will prove two of its low-dose shots work in
children younger than 5. Moderna also has filed FDA applications for older
kids, although the agency hasn’t ruled on them.
The FDA already has set tentative dates in June to publicly
review data on COVID-19 vaccines for tots under 5, from either or both
companies.
0 comments:
Post a Comment